Used in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly PROTACs (proteolysis-targeting chimeras). Its structure enables linkage between an E3 ligase binder and a target protein ligand, facilitating ubiquitination and subsequent degradation of disease-related proteins. Commonly employed in oncology and neurodegenerative disease studies due to its ability to enhance selectivity and potency in drug candidates. The stereochemistry supports optimal binding orientation in complex biological environments.